Impact of the CHA2DS2-VASc Score on Anticoagulation Recommendations for Atrial Fibrillation

被引:79
作者
Mason, Pamela K. [1 ]
Lake, Douglas E. [1 ]
DiMarco, John P. [1 ]
Ferguson, John D. [1 ]
Mangrum, J. Michael [1 ]
Bilchick, Kenneth [1 ]
Moorman, Liza P. [1 ]
Moorman, J. Randall [1 ]
机构
[1] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA
关键词
Anticoagulation; Atrial Fibrillation; Stroke; Warfarin; EURO HEART SURVEY; PREDICTING STROKE; TASK-FORCE; RISK; WARFARIN; PREVENTION; MANAGEMENT;
D O I
10.1016/j.amjmed.2011.09.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The Congestive heart failure, Hypertension, Age >= 75 years, Diabetes mellitus, Stroke (CHADS(2)) score is used to predict the need for oral anticoagulation for stroke prophylaxis in patients with atrial fibrillation. The Congestive heart failure, Hypertension, Age >= 75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category (CHA (2) DS (2)-VASc) schema has been proposed as an improvement. Our objective is to determine how adoption of the CHA(2)DS(2)-VASc score alters anticoagulation recommendations. METHODS: Between 2004 and 2008, 1664 patients were seen at the University of Virginia Atrial Fibrillation Center. We calculated the CHADS(2) and CHA(2)DS(2)-VASc scores for each patient. The 2006 American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for atrial fibrillation management were used to determine anticoagulation recommendations based on the CHADS(2) score, and the 2010 European Society of Cardiology guidelines were used to determine anticoagulation recommendations based on the CHA(2)DS(2)-VASc score. RESULTS: The average age was 62 +/- 13 years, and 34% were women. Average CHADS(2) and CHA(2)DS(2)-VASc scores were 1.1 +/- 1.1 and 1.8 +/- 1.5, respectively (P <.0001). The CHADS(2) score classified 33% as requiring oral anticoagulation. The CHA(2)DS(2)-VASc score classified 53% as requiring oral anticoagulation. For women, 31% had a CHADS(2) score >= 2, but 81% had a CHA(2)DS(2)-VASc score >= 2 (P = .0001). Also, 32% of women with a CHADS(2) score of zero had a CHA(2)DS(2)-VASc score >= 2. For men, 25% had a CHADS(2) score >= 2, but 39% had a CHA(2)DS(2)-VASc score >= 2 (P<.0001). CONCLUSION: Compared with the CHADS(2) score, the CHA(2)DS(2)-VASc score more clearly defines anticoagulation recommendations. Many patients, particularly older women, are redistributed from the low-to high-risk categories. (c) 2012 Elsevier Inc. All rights reserved. circle The American Journal of Medicine (2012) 125, 603.e1-603.e6
引用
收藏
页码:603.e1 / 603.e6
页数:6
相关论文
共 20 条
[2]   Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[3]   INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
LEVY, D ;
VAZIRI, SM ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11) :840-844
[4]   Stroke prevention in the high-risk atrial fibrillation patient: Medical management [J].
Broukhim M. ;
Halperin J.L. .
Current Cardiology Reports, 2011, 13 (1) :9-17
[5]   RISK FOR SYSTEMIC EMBOLIZATION OF ATRIAL-FIBRILLATION WITHOUT MITRAL-STENOSIS [J].
CABIN, HS ;
CLUBB, KS ;
HALL, C ;
PERLMUTTER, RA ;
FEINSTEIN, AR .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (16) :1112-1116
[6]  
Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]
[7]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[8]   WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
EZEKOWITZ, MD ;
BRIDGERS, SL ;
JAMES, KE ;
CARLINER, NH ;
COLLING, CL ;
GORNICK, CC ;
KRAUSESTEINRAUF, H ;
KURTZKE, JF ;
NAZARIAN, SM ;
RADFORD, MJ ;
RICKLES, FR ;
SHABETAI, R ;
DEYKIN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) :1406-1412
[9]   Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation [J].
Fang, Margaret C. ;
Go, Alan S. ;
Chang, Yuchiao ;
Borowsky, Leila ;
Pomernacki, Niela K. ;
Singer, Daniel E. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (08) :810-815
[10]   Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].
Gage, BF ;
Waterman, AD ;
Shannon, W ;
Boechler, M ;
Rich, MW ;
Radford, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870